RESEARCH & DEVELOPMENT
Our R&D programs focus on both disease prevention and immune modulation.
AT THE FOREFRONT
OF VACCINE TECHNOLOGY
The company is actively working on:
- mRNA vaccines for viral and metabolic diseases
- Sub-unit vaccines for respiratory and emerging infections
- Therapeutic cancer vaccines targeting neoantigens
- Combined microneedle and transfection-enhanced delivery systems for next-generation immunotherapies
Pre-clinical work is performed in collaboration with academic and clinical partners across the UK and internationally. Manufacturing and formulation activities are supported by our GMP-licensed partner facility, ensuring a smooth transition from research to clinical trial production.
MANUFACTURING AND SCALE-UP
Landmark Vaccines benefits from direct access to GMP infrastructure for both vaccine formulation and microneedle device manufacture. This integrated approach ensures complete control of quality, process development, and scale-up from laboratory concept to clinical trial material.
Our manufacturing ecosystem includes:
- GMP cleanroom facilities for aseptic preparation and filling
- Capabilities for both liquid and solid-state vaccine formulations
- In-house analytical and release testing
- Quality systems aligned with MHRA and EU Annex 1 standards
This allows Landmark Vaccines to operate efficiently as both a developer and a clinical-stage manufacturer.
